Oxygen Inhalation Therapy
Conditions
Keywords
Oxygen, Insufflation, COPD, High Flow Treatment
Brief summary
Evaluation of Safety and Efficacy of Shorttime TNI Treatment in Patients with COPD Acute testing of oxygen demand using TNI vs. standard oxygen application in stable COPD patients An investigator-initiated, prospective, controlled, multicenter study
Detailed description
TNI, the nasal insufflation of a high flow of warm, humidified air, is an extremely comfortable and uncomplicated alternative to numerous other approaches in non-invasive ventilation (NIV). Up to now, NIV therapy could only be applied by masks with the associated complications as patients could not tolerate high airflow delivered by a thin nasal cannula without humidification and warming, thus causing concomitant negative effects. The new therapy TNI shows a high rate of acceptance by children, too. At present, there are two different types of devices available for nasal insufflation in clinics: TNI 20s, an air humidifier for clinical compressed air, and the TNI20 oxy, an air humidifier for clinical compressed air, which can be combined with oxygen. TNI 20 oxy The system, which is unique throughout the world, is optimized for the application of flows of up to 20L/min and fulfils the minimum requirements of the American Society of Testing and Materials for a high flow air humidifier in the non-invasive application of 10 mg H2O/L (equivalent to about 60% rel. humidity at an ambient temperature of 22°C) for the air humidity. The warming of the air flow by 5-15°C can be adjusted relative to the ambient temperature. Condensation is prevented in the nasal applicator by heating the tube as far as the nostrils. The device automatically controls humidity and temperature depending on the prevailing ambient conditions. The TNI®20s can be attached to the hospital infrastructure by means of a standard pressure regulator.
Interventions
DEVICENasal oxygen insufflation with a TNI 20 oxy device
Nasal oxygen insufflation with a TNI 20 oxy device
DEVICEStandard Nasal Insufflation of oxygen
Standard Nasal Insufflation of oxygen
Sponsors
Medical University Innsbruck
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
\- COPD patients with an indication for long-term oxygen therapy Age 30 - 80 years COPD GOLD °III
Exclusion criteria
\- Clinical instability of the patient No lung function testing possible Exacerbation within the last 14 days prior to inclusion into the study Serious concomitant diseases that may jeopardize the inclusion of the patient into the study from the investigator's point of view Anaemia, defined by a haemoglobin \<10 G/L Patients with hypercapnia, defined by a paCO \<46mmHg Participation of the patient in any other ongoing study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PaO2 | Measures at Baseline and after 60 min | Change in the partial oxygen pressure in the arterial blood (blood gas analysis) at a defined oxygen flow rate (L/min) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| O2 % | Measures at Baseline and after 60 min | Change in the oxygen saturation in the arterial blood (blood gas analysis) at a defined oxygen flow rate (L/min) |
| PaCO2 | Measures at Baseline and after 60 min | Change in the partial carbon dioxide pressure in the arterial blood (blood gas analysis) at a defined oxygen flow rate (L/min) |
| AaDO2 | Measures at Baseline and after 60 min | Change in the AaDO2 in the peripheral blood at a defined oxygen flow rate (L/min) |
| RV and TLC | Measures at Baseline and after 60 min | Safety of the device in COPD °III or IV patients: No increase in the residual volume (RV) and the total lung capacity (TLC) \> 15% of the mean actual value at visits 1 and 2 (measurement 60 + 10 minutes after oxygen insufflation with a TNI system). |
Countries
Austria, Germany, Switzerland
Contacts
Primary ContactChristian M Kaehler, MD
Outcome results
None listed